Toujeo© is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of <6 years. Safety and efficacy in patients <6 years have not been established.3 Toujeo© is contraindicated in case of hypersensitivity to the active substance or to any of the excipients.3 The most common adverse events observed with Toujeo® are hypoglycemia (very common), lipohypertrophy and injection site reactions (common). Consult the full SmPC for full list/details of adverse events.3 This material is intended for healthcare professionals only and was developed based on the EU Summary of Product Characteristics (SmPC) which is available in our booth. You can also access the full EU SmPC by flashing the QR code below. La Ficha técnica en español con precio y condiciones de reembolso está disponible en el estand. Please consult the prescribing information in your country of practice as information may vary from country to country. Toujeo© may not be available in all countries worldwide.
1. Battelino T, et al. Diabetes Ther 2020;11(4):1017-1027;
2. Battelino T, et al. Diabetes Ther 2020;11(7):1907-1908;
3. Toujeo® European Summary of Product Characteristics (July 2020).